In vivo administration of liposomal vincristine sensitizes drug-resistant human solid tumors
- PMID: 15146568
- DOI: 10.1002/ijc.20174
In vivo administration of liposomal vincristine sensitizes drug-resistant human solid tumors
Abstract
Here we evaluated the antitumor efficacy of vincristine (VCR) encapsulated in sphingomyelin/cholesterol liposomes (SM/Chol) on drug-resistant human solid tumors. We firstly used the M14 human melanoma line and the counterpart resistant derivative, M14/R. The M14/R, selected after doxorubicin exposure, was cross resistant to VCR: the in vitro treatment with free VCR reduced the survival of M14, while M14/R line was completely resistant to VCR. Encapsulation in liposomes improved the efficacy of VCR in M14 cells and sensitized the M14/R line to the drug. Experiments in vivo confirmed these results. The treatment of M14 bearing mice with VCR resulted in marked reduction of tumor growth, while no antitumoral effect was observed in M14/R tumors. The administration of VCR encapsulated in liposomes was able to sensitize M14/R tumors to the drug, the antitumoral effect being comparable to that observed in M14 tumors after the same treatment. By injecting animals with the same dose of liposomal VCR fractionated into 3 daily injections and administering repeated cycles of treatment, to a marked improvement of the antitumor activity of liposomal VCR was observed. TUNEL assay in tumor sections indicated that the improved efficacy of liposomal VCR was related to the induction of massive necrosis and apoptosis. To confirm the efficacy of liposomal VCR on drug-resistant tumors, MCF7 breast and LoVo colon carcinomas, sensitive and resistant to VCR treatment, were also employed. The results showed that the treatment with liposomal VCR of mice bearing breast or colon resistant tumors reduced the tumor mass and delayed the tumor regrowth to the same extent observed in the sensitive counterpart. Together, these results demonstrate the ability of VCR encapsulated in liposomes in sensitizing drug resistant tumors of different histotypes.
Copyright 2004 Wiley-Liss, Inc.
Similar articles
-
Marqibo® (vincristine sulfate liposome injection) improves the pharmacokinetics and pharmacodynamics of vincristine.Cancer Chemother Pharmacol. 2013 Mar;71(3):555-64. doi: 10.1007/s00280-012-2042-4. Epub 2012 Dec 5. Cancer Chemother Pharmacol. 2013. PMID: 23212117 Free PMC article. Review.
-
Improved therapeutic responses in a xenograft model of human B lymphoma (Namalwa) for liposomal vincristine versus liposomal doxorubicin targeted via anti-CD19 IgG2a or Fab' fragments.Clin Cancer Res. 2004 Feb 1;10(3):1100-11. doi: 10.1158/1078-0432.ccr-03-0041. Clin Cancer Res. 2004. PMID: 14871990
-
STI571 combined with vincristine greatly suppressed the tumor formation of multidrug-resistant K562 cells in a human-nude mice xenograft model.Chin Med J (Engl). 2006 Jun 5;119(11):911-8. Chin Med J (Engl). 2006. PMID: 16780770
-
Enhancement of vincristine cytotoxicity in drug-resistant cells by simultaneous treatment with onconase, an antitumor ribonuclease.J Natl Cancer Inst. 1996 Jun 5;88(11):747-53. doi: 10.1093/jnci/88.11.747. J Natl Cancer Inst. 1996. PMID: 8637029
-
Efficacy and Safety of Vincristine Sulfate Liposome Injection in the Treatment of Adult Acute Lymphocytic Leukemia.Oncologist. 2016 Jul;21(7):840-7. doi: 10.1634/theoncologist.2015-0391. Epub 2016 Jun 21. Oncologist. 2016. PMID: 27328933 Free PMC article. Review.
Cited by
-
A Pilot Phase II Study of the Feasibility and Efficacy of Vincristine Sulfate Liposome Injection in Patients With Relapsed or Refractory Acute Myeloid Leukemia.J Hematol. 2021 Feb;10(1):1-7. doi: 10.14740/jh771. Epub 2021 Feb 6. J Hematol. 2021. PMID: 33643502 Free PMC article.
-
Disulfide cross-linked micelles for the targeted delivery of vincristine to B-cell lymphoma.Mol Pharm. 2012 Jun 4;9(6):1727-35. doi: 10.1021/mp300128b. Epub 2012 May 1. Mol Pharm. 2012. PMID: 22530955 Free PMC article.
-
Treatment of acute lymphoblastic leukaemia : a new era.Drugs. 2007;67(15):2153-71. doi: 10.2165/00003495-200767150-00004. Drugs. 2007. PMID: 17927282 Review.
-
Phase 1 multicenter study of vincristine sulfate liposomes injection and dexamethasone in adults with relapsed or refractory acute lymphoblastic leukemia.Cancer. 2009 Dec 1;115(23):5490-8. doi: 10.1002/cncr.24632. Cancer. 2009. PMID: 19708032 Free PMC article. Clinical Trial.
-
Marqibo® (vincristine sulfate liposome injection) improves the pharmacokinetics and pharmacodynamics of vincristine.Cancer Chemother Pharmacol. 2013 Mar;71(3):555-64. doi: 10.1007/s00280-012-2042-4. Epub 2012 Dec 5. Cancer Chemother Pharmacol. 2013. PMID: 23212117 Free PMC article. Review.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources